Cardiff business receives equity from Finance Wales
AssayMetrics to commercialise prototype plate reader for use in the pharmaceutical and biotechnology industries
The early stage business has also received investment from a syndicate of business angels.
Dr Pierre Graves formed AssayMetrics in 2004. The following year, two senior scientists, Dr John Whateley and Dr Anthony Smith, joined the company.
In 2006 the company launched its chemical dye reagents, which are used in the biotechnology and pharmaceutical industries for compound screening. It subsequently developed its own Puretime novel fluorescent dye reagents before embarking on the development of a prototype plate reader, which added analytical instrumentation to its dye-based products.
According to AssayMetrics, a number of customers have expressed a wish to act as beta test sites for this plate reader.
‘The drug discovery market continues to grow despite the recession and we are delighted to be able to place a technology in the hands of customers that will make the process faster and more efficient,’ said Graves, chief executive of Assaymetrics.
Finance Wales provides commercial funding to small and medium-sized businesses throughout Wales, enabling them to realise their potential for innovation and growth.
A subsidiary of the Welsh Assembly Government, Finance Wales manages funds of more than £280m and has invested more than £157m in Wales-based businesses.
You may also like
Manufacturing
Key drivers behind the rise of microsphere drug delivery systems
Read moreMicrospheres shift drug delivery from broad distribution to precise targeting. These systems improve therapeutic consistency, lower systemic exposure, and adapt to complex treatment regimens. Their growth reflects progress in polymer science, pharmacokinetics, and the push for more individualised care in clinical settings. Let’s explore some of the key drivers behind the rise of microsphere drug delivery systems and look ahead to predict future growth trends
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Key drivers behind the rise of microsphere drug delivery systems
Microspheres shift drug delivery from broad distribution to precise targeting. These systems improve therapeutic consistency, lower systemic exposure, and adapt to complex treatment regimens. Their growth reflects progress in polymer science, pharmacokinetics, and the push for more individualised care in clinical settings. Let’s explore some of the key drivers behind the rise of microsphere drug delivery systems and look ahead to predict future growth trends
Finance
Syngene International extends long-term research collaboration with Bristol Myers Squibb until 2035
Syngene International, a global contract research, development, and manufacturing organisation (CRDMO), announces the extension of its long-standing strategic collaboration with Bristol Myers Squibb through 2035
Finance
Novo Nordisk Foundation commits DKK 5.5bn to boost European life sciences innovation
The long-term funding will enable the BioInnovation Institute to expand into new scientific fields and European markets, strengthening translation of academic research into commercial life sciences innovation